ASH 2018 | Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
The PHOENIX clinical trial investigated the addition of ibrutinib to R-CHOP in a pre-selected subpopulation of patients with non-GCB and ABC diffuse large B-cell lymphoma (NCT01855750). Although this trial did not meet the primary endpoint of event-free survival, upon further analysis a link was found between age and response to treatment. Anas Younes, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the details of the sub-analysis conducted, which were presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up